Bernhard Landwehrmeyer
#181,045
Most Influential Person Now
Researcher
Bernhard Landwehrmeyer's AcademicInfluence.com Rankings
Bernhard Landwehrmeyerbiology Degrees
Biology
#15382
World Rank
#19347
Historical Rank
Neuroscience
#2765
World Rank
#2838
Historical Rank
Download Badge
Biology
Why Is Bernhard Landwehrmeyer Influential?
(Suggest an Edit or Addition)According to Wikipedia, Georg Bernhard Landwehrmeyer FRCP is a German neurologist and neuroscientist in the field of neurodegeneration primarily focusing on Huntington's disease. Landwehrmeyer is a professor of neurology at Ulm University Hospital. He was one of the founders of the European Huntington's Disease Network in 2004 and was chairman of its executive committee until 2014.
Bernhard Landwehrmeyer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values (2006) (1965)
- Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes (2010) (824)
- Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis (2011) (530)
- Identification of Genetic Factors that Modify Clinical Onset of Huntington’s Disease (2015) (420)
- Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. (2002) (415)
- Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. (2002) (306)
- CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion (2012) (263)
- Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study (1999) (245)
- CAG Repeat Not Polyglutamine Length Determines Timing of Huntington’s Disease Onset (2019) (236)
- Metabotropic glutamate receptors are differentially regulated during development (1994) (231)
- An Isoform of Ataxin‐3 Accumulates in the Nucleus of Neuronal Cells in Affected Brain Regions of SCA3 Patients (1998) (213)
- Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study (2017) (208)
- Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons (1995) (190)
- Expression of group one metabotropic glutamate receptor subunit mRNAs in neurochemically identified neurons in the rat neostriatum, neocortex, and hippocampus. (1997) (188)
- Weight loss in Huntington disease increases with higher CAG repeat number (2008) (179)
- Expression of NMDAR2D glutamate receptor subunit mRNA in neurochemically identified interneurons in the rat neostriatum, neocortex and hippocampus. (1996) (177)
- Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice. (2000) (173)
- Riluzole in Huntington's disease: a 3‐year, randomized controlled study (2007) (169)
- Localization of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal ganglia (1999) (164)
- Protein surveillance machinery in brains with spinocerebellar ataxia type 3: Redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions (2002) (145)
- Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the rat. (1999) (144)
- A single nucleotide polymorphism in the coding region of PGC-1α is a male-specific modifier of Huntington disease age-at-onset in a large European cohort (2014) (144)
- Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from event-related fMRI. (2007) (132)
- The gene coding for PGC-1α modifies age at onset in Huntington's Disease (2009) (131)
- An Improved Approach to Prepare Human Brains for Research (1995) (128)
- Expression of N‐Methyl‐D‐Aspartate receptor subunit mRNAs in the human brain: Hippocampus and cortex (1998) (124)
- Data Analytics from Enroll‐HD, a Global Clinical Research Platform for Huntington's Disease (2017) (120)
- Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. (1999) (118)
- Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease. (2016) (116)
- Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study (2015) (116)
- Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease (2002) (115)
- Visualization of dopamine D1, D2 and D3 receptor mRNA's in human and rat brain (1992) (113)
- Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum (2000) (111)
- SCA7 mouse models show selective stabilization of mutant ataxin-7 and similar cellular responses in different neuronal cell types. (2001) (103)
- Molecular and functional characterization of recombinant human metabotropic glutamate receptor subtype 5 (1995) (103)
- Myopathy as a first symptom of Huntington's disease in a Marathon runner (2007) (91)
- A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset. (2012) (91)
- Cortical dysfunction in patients with Huntington's disease during working memory performance (2009) (83)
- Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression (2017) (78)
- Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis (2018) (75)
- Neurofilament heavy‐chain NfHSMI35 in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes (2006) (70)
- Global cerebral atrophy in early stages of Huntington's disease: quantitative MRI study (2004) (69)
- Glutamate receptor expression in rat striatum: Effect of deafferentation (1994) (68)
- Suicidal ideation in a European Huntington's disease population. (2013) (68)
- Expression of N‐Methyl‐D‐Aspartate receptor subunit mRNAs in the human brain: Striatum and globus pallidus (1998) (66)
- Default-mode network changes in preclinical Huntington's disease (2012) (65)
- Expression Analysis of Ataxin‐7 mRNA and Protein in Human Brain: Evidence for a Widespread Distribution and Focal Protein Accumulation (2000) (64)
- Update on Huntington's disease: advances in care and emerging therapeutic options. (2015) (62)
- A randomized, placebo‐controlled trial of AFQ056 for the treatment of chorea in Huntington's disease (2015) (60)
- High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo. (2007) (54)
- Mice transgenic for exon 1 of Huntington's disease: properties of cholinergic and dopaminergic pre‐synaptic function in the striatum (2003) (53)
- Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study (2019) (53)
- Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's disease (2011) (52)
- Expression of N-methyl- d-aspartate glutamate receptor subunits in the prefrontal cortex of the rat (1996) (50)
- Alternative splicing of the 5′‐sequences of the mouse EAAT2 glutamate transporter and expression in a transgenic model for amyotrophic lateral sclerosis (2002) (50)
- Imaging of activated microglia with PET and [11C]PK 11195 in corticobasal degeneration (2004) (49)
- Strychnine-sensitive glycine receptors in rat caudatoputamen are expressed by cholinergic interneurons (2000) (44)
- Corrigendum to “Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values” [Pain 123 (2006) 231–243] (2006) (44)
- Expression of N‐Methyl‐D‐Aspartate receptor subunit mRNA in the human brain: Mesencephalic dopaminergic neurons (1998) (42)
- Visual system integrity and cognition in early Huntington's disease (2014) (42)
- The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington's disease. (2018) (41)
- Abnormal cerebellar volume and corticocerebellar dysfunction in early manifest Huntington’s disease (2015) (40)
- Abnormal resting-state connectivity of motor and cognitive networks in early manifest Huntington's disease (2014) (39)
- Changes in NMDA receptor subunit gene expression in the rat brain following withdrawal from forced long-term ethanol intake (2000) (38)
- Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease (2009) (35)
- Modulation of cortical acetylcholine release by serotonin: the role of substance P interneurons (1996) (33)
- Up-regulation of D3 dopaminergic receptor mRNA in the core of the nucleus accumbens accompanies the development of seizures in a genetic model of absence-epilepsy in the rat. (2001) (33)
- The Human N‐Methyl‐d‐Aspartate Receptor 2C Subunit: Genomic Analysis, Distribution in Human Brain, and Functional Expression (1998) (31)
- Simultaneous isotopic and nonisotopic in situ hybridization histochemistry with cRNA probes. (1998) (31)
- Localization of alternatively spliced NMDAR1 glutamate receptor isoforms in rat striatal neurons (1999) (31)
- Association of CAG Repeats With Long-term Progression in Huntington Disease. (2019) (30)
- Cellular Distribution of NMDA Glutamate Receptor Subunit mRNAs in the Human Cerebellum (1997) (30)
- Motor network structure and function are associated with motor performance in Huntington’s disease (2016) (28)
- Overlap between age-at-onset and disease-progression determinants in Huntington disease (2018) (28)
- 5-HT1D-like receptors inhibit the release of endogenously formed [3H]GABA in human, but not in rabbit, neocortex (1996) (26)
- Timing and Impact of Psychiatric, Cognitive, and Motor Abnormalities in Huntington Disease (2021) (25)
- NMDA receptor gene variations as modifiers in Huntington disease: a replication study (2011) (24)
- Altered Ca2+ signaling in skeletal muscle fibers of the R6/2 mouse, a model of Huntington’s disease (2014) (24)
- IT15 gene expression in fetal human brain (1994) (23)
- Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion (2020) (23)
- FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations (2019) (22)
- Fully Automated Atlas-Based MR Imaging Volumetry in Huntington Disease, Compared with Manual Volumetry (2011) (21)
- Suicidal ideation and suicidal behavior according to the C-SSRS in a European cohort of Huntington's disease gene expansion carriers. (2018) (21)
- TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. (2012) (20)
- Genetic Risk Underlying Psychiatric and Cognitive Symptoms in Huntington’s Disease (2019) (20)
- Characterization of opioid receptor types modulating acetylcholine release in septal regions of the rat brain (2000) (19)
- Discrepancies in reporting the CAG repeat lengths for Huntington's disease (2011) (18)
- The European Reference Network for Rare Neurological Diseases (2021) (17)
- Fast-to-Slow Transition of Skeletal Muscle Contractile Function and Corresponding Changes in Myosin Heavy and Light Chain Formation in the R6/2 Mouse Model of Huntington’s Disease (2016) (17)
- Natural variation in sensory‐motor white matter organization influences manifestations of Huntington's disease (2016) (16)
- Human transmissible spongiform encephalopathies. (1998) (16)
- Longitudinal task-negative network analyses in preclinical Huntington’s disease (2014) (15)
- Altered Ca 2+ signaling in skeletal muscle fibers of the R6/2 mouse, a model of Huntington’s disease (2014) (15)
- Opioid receptor-mediated control of acetylcholine release in human neocortex tissue (1996) (14)
- Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington’s disease (2004) (14)
- Enroll-HD: An Integrated Clinical Research Platform and Worldwide Observational Study for Huntington's Disease (2021) (13)
- Exome sequencing of individuals with Huntington’s disease implicates FAN1 nuclease activity in slowing CAG expansion and disease onset (2022) (13)
- High-resolution respirometry of fine-needle muscle biopsies in pre-manifest Huntington’s disease expansion mutation carriers shows normal mitochondrial respiratory function (2017) (12)
- Objective assessment of gait and posture in premanifest and manifest Huntington disease - A multi-center study. (2018) (12)
- Defining pediatric huntington disease: Time to abandon the term Juvenile Huntington Disease? (2019) (12)
- Combined cerebral atrophy score in Huntington's disease based on atlas-based MRI volumetry: Sample size calculations for clinical trials. (2019) (11)
- Observing Huntingtons Disease: the European Huntingtons Disease Networks REGISTRY (2010) (10)
- N-methyl-d-aspartate receptor subunit mRNA expression in human retinal ganglion cells (2000) (10)
- Intact sensory-motor network structure and function in far from onset premanifest Huntington’s disease (2017) (9)
- Improving binding potential analysis in [11C]raclopride PET studies using cluster analysis. (2004) (9)
- Cerebrospinal Fluid Levels of Prodynorphin‐Derived Peptides are Decreased in Huntington's Disease (2020) (9)
- Aspartate, glutamate, glutamine, glycine and γ-aminobutyric acid in human bioptic neocortical areas: comparison to autoptic tissue (1997) (9)
- Olfactory screening of Parkinson’s Disease patients and healthy subjects in China and Germany: A study of cross-cultural adaptation of the Sniffin’ Sticks 12-identification test (2019) (9)
- Efficacy, Safety, and Tolerability of Pridopidine in Huntington Disease (HD): Results from the Phase II, Double-blind, Placebo-controlled, Dose-Ranging Study, Pride-HD (P2.005) (2017) (9)
- Identification of symbol digit modality test score extremes in Huntington's disease (2019) (8)
- [Functional imaging of cognitive processes in Huntington's disease and its presymptomatic mutation carriers]. (2008) (7)
- Current Pharmacological Management in Juvenile Huntington’s Disease (2012) (7)
- Catatonia: looking back and moving forward. (2022) (6)
- D22 Compensation in preclinical huntington’s disease: evidence from the track-on HD study (2016) (5)
- Meaningful and Measurable Health Domains in Huntington's Disease: Large-Scale Validation of the Huntington's Disease Health-Related Quality of Life Questionnaire Across Severity Stages. (2019) (5)
- Research priorities for rare neurological diseases: a representative view of patient representatives and healthcare professionals from the European Reference Network for Rare Neurological Diseases (2020) (4)
- HAP40 protein levels are huntingtin-dependent and decrease in Huntington disease (2021) (4)
- [3H]Acetycholine release in rat striatal slices is not subject to dopamine heteroreceptor supersensitivity 30 months after 6-hydroxydopamine lesion of the substantia nigra (2001) (4)
- Current Pharmacological Management in Juvenile Huntington's Disease. (2012) (3)
- Effect of Body Weight on Age at Onset in Huntington Disease (2021) (3)
- Glutamate receptor genes in Parkinson's disease. (1996) (3)
- FAN1 nuclease activity affects CAG expansion and age at onset of Huntington’s disease (2021) (3)
- How to Arrange Follow-Up Time-Intervals for Longitudinal Brain MRI Studies in Neurodegenerative Diseases (2021) (2)
- A Prospective Registry Study in a Global Huntington's Disease Cohort A CHDI Foundation Project (2011) (2)
- Ubiquitination and the proteasome rather than caspase‐3‐mediated C‐terminal cleavage are involved in the EAAT2 degradation by staurosporine‐induced cellular stress (2020) (2)
- D02 Discrepancies in reporting the upper CAG repeat allele between a central EHDN and local laboratories for centres participating in the REGISTRY project (2010) (2)
- Genetic overlap between psychiatric disorders and neuropsychiatric symptoms in HD (2019) (2)
- Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington’s and Parkinson’s disease (2022) (1)
- Validation Study of a German Cognitive Battery for Huntington’s Disease: Relationship Between Cognitive Performance, Functional Decline, and Disease Burden (2020) (1)
- H31 Dysphagia in huntington´s disease – an observational study (2018) (1)
- The onset and prevalence of motor and psychiatric symptoms in Huntington’s disease (2020) (1)
- Hypothyroidism, Congenital (2005) (1)
- Current Pharmacological Management in Juvenile Huntington's Disease. (2012) (1)
- [Gene-selective treatment approaches for Huntington's disease]. (2020) (1)
- Commentary: Acanthocytes identified in Huntington's disease (2022) (1)
- Corrigendum to "Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's disease" [Parkinsonism Relat. Disord. 25C (2016) 58-64]. (2016) (1)
- 2.3.3 A GENOME-WIDE ANALYSIS IN THE EUROPEAN HD POPULATION (2012) (0)
- D19 Purification of extracellular vesicles from human control and HTT mutant carrier CSF and quantitative analysis of their RNA content (2022) (0)
- Abstracts Second Congress of the European Society for Clinical Neuropharmacology (1995) (0)
- Feuerstein 1996 Opioid receptor-mediated control of acetylcholine (2015) (0)
- D04 Blood-CSF barrier function and CSF flow influence CSF biomarkers in huntington’s disease (2018) (0)
- MRI-based studies on Huntington´s disease: variability of extrastriatal volume changes (2019) (0)
- F01 The European HD Network REGISTRY: Current status and future directions (2010) (0)
- transgenic mouse expressing Altered Ca 2 + signaling in skeletal muscle fibers of the R 6 / 2 mouse , a model of Huntington ’ s disease (0)
- Interview: Following a standard of care for Huntington’s disease (2012) (0)
- Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY. (2010) (0)
- F25 Huntington’s disease health-related quality of life questionnaire (HDQOL): further validation (2018) (0)
- A12 Loss of proteostasis in huntington disease – lessons from cockayne syndrome (2022) (0)
- F53 Acoustic analysis of oral diadochokinesis in early-to-moderate Huntington disease (2022) (0)
- Study Protocol for the Development of a European eHealth Platform to Improve Quality of Life in Individuals With Huntington's Disease and Their Partners (HD-eHelp Study): A User-Centered Design Approach (2021) (0)
- The timing and impact of psychiatric, cognitive and motor abnormalities in Huntington’s disease (2020) (0)
This paper list is powered by the following services:
Other Resources About Bernhard Landwehrmeyer
What Schools Are Affiliated With Bernhard Landwehrmeyer?
Bernhard Landwehrmeyer is affiliated with the following schools:
